Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effects of empagliflozin on cardiac remodeling and myocardial sympathetic nervous system in diabetic patients with chronic heart failure
2019-002202-43Phase 4Terminated
- Sponsor
- Policlinico Federico II
- Start
- Oct 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, single-arm trial of empagliflozin in type 2 diabetes mellitus (T2DM) and chronic heart failure (CHF), sponsored by Policlinico Federico II. Primary endpoint: Left ventricular remodeling and function. Started Oct 2020; status: terminated.
02
Drugs
empagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)chronic heart failure (CHF)
Beyond the preview
Go deeper on 2019-002202-43.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002202-43.